Recap: Aptose Biosciences Q4 Earnings
Portfolio Pulse from Benzinga Insights
Aptose Biosciences (NASDAQ:APTO) reported Q4 earnings, beating estimates by 9.0% with an EPS of $-1.44 against an expected $-1.59. However, revenue remained unchanged from the previous year. Despite beating last quarter's EPS estimates, the share price dropped by 24.0% the following day.
March 26, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aptose Biosciences reported better than expected Q4 earnings but saw no change in revenue from the previous year.
Despite beating earnings estimates, the lack of revenue growth and historical context of a significant share price drop following the last earnings beat suggest a potential short-term negative impact on APTO's stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100